Clarithromycin Drug Interactions
263Total Interactions
138Severe
115Moderate
10Mild
| Drug | Severity | Summary |
|---|---|---|
| Abemaciclib | SEVERE | Clarithromycin is predicted to increase the exposure to Abemaciclib. Manufacturer advises avoid o... |
| Acalabrutinib | SEVERE | Clarithromycin is predicted to increase the exposure to Acalabrutinib. Manufacturer advises avoid. |
| Acenocoumarol | SEVERE | Clarithromycin increases the anticoagulant effect of Acenocoumarol. Manufacturer advises monitor ... |
| Alfentanil | SEVERE | Clarithromycin is predicted to increase the exposure to Alfentanil. Manufacturer advises monitor ... |
| Atazanavir | SEVERE | Atazanavir is predicted to increase the exposure to Clarithromycin. Manufacturer advises adjust d... |
| Atorvastatin | SEVERE | Clarithromycin is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid ... |
| Avacopan | SEVERE | Clarithromycin is predicted to increase the exposure to Avacopan. Manufacturer advises monitor. |
| Avanafil | SEVERE | Clarithromycin is predicted to increase the exposure to Avanafil. Manufacturer advises avoid. |
| Betamethasone | SEVERE | Clarithromycin is predicted to increase the exposure to Betamethasone. Manufacturer advises avoid... |
| Bosutinib | SEVERE | Clarithromycin is predicted to increase the exposure to Bosutinib. Manufacturer advises avoid or ... |
| Brentuximab vedotin | SEVERE | Clarithromycin is predicted to increase the risk of neutropenia when given with Brentuximab vedot... |
| Brigatinib | SEVERE | Clarithromycin is predicted to increase the exposure to Brigatinib. Manufacturer advises avoid or... |
| Bromocriptine | SEVERE | Clarithromycin increases the exposure to Bromocriptine. Manufacturer advises caution. |
| Budesonide | SEVERE | Clarithromycin is predicted to increase the exposure to Budesonide. Manufacturer advises avoid or... |
| Buprenorphine | SEVERE | Clarithromycin is predicted to increase the exposure to Buprenorphine. Manufacturer advises monit... |
| Buspirone | SEVERE | Clarithromycin is predicted to increase the exposure to Buspirone. Manufacturer advises adjust Bu... |
| Cabazitaxel | SEVERE | Clarithromycin is predicted to increase the exposure to Cabazitaxel. Manufacturer advises avoid o... |
| Cabergoline | SEVERE | Clarithromycin is predicted to increase the concentration of Cabergoline. Manufacturer advises av... |
| Carbamazepine | SEVERE | Clarithromycin slightly increases the concentration of Carbamazepine. Manufacturer advises monito... |
| Cariprazine | SEVERE | Clarithromycin is predicted to moderately increase the exposure to Cariprazine. Manufacturer advi... |
| Ceritinib | SEVERE | Clarithromycin is predicted to increase the exposure to Ceritinib. Manufacturer advises avoid or ... |
| Chloroquine | SEVERE | Clarithromycin might increase the risk of serious cardiovascular adverse effects when given with ... |
| Ciclesonide | SEVERE | Clarithromycin is predicted to increase the exposure to Ciclesonide. Manufacturer advises avoid o... |
| Ciclosporin | SEVERE | Clarithromycin increases the concentration of Ciclosporin. Manufacturer advises caution. |
| Cobimetinib | SEVERE | Clarithromycin is predicted to increase the exposure to Cobimetinib. Manufacturer advises avoid o... |
| Colchicine | SEVERE | Clarithromycin is predicted to increase the exposure to Colchicine. Manufacturer advises avoid po... |
| Dapoxetine | SEVERE | Clarithromycin is predicted to moderately increase the exposure to Dapoxetine. Manufacturer advis... |
| Daridorexant | SEVERE | Clarithromycin is predicted to increase the exposure to Daridorexant. Manufacturer advises avoid. |
| Darifenacin | SEVERE | Clarithromycin is predicted to markedly to very markedly increase the exposure to Darifenacin. Ma... |
| Darunavir | SEVERE | Darunavir boosted with ritonavir is predicted to increase the exposure to Clarithromycin. Manufac... |
| Dasatinib | SEVERE | Clarithromycin is predicted to increase the exposure to Dasatinib. Manufacturer advises avoid or ... |
| Deflazacort | SEVERE | Clarithromycin is predicted to increase the exposure to Deflazacort. Manufacturer advises avoid o... |
| Delamanid | SEVERE | Clarithromycin very slightly increases the exposure to Delamanid. Manufacturer advises caution an... |
| Deutivacaftor | SEVERE | Clarithromycin is predicted to increase the exposure to Deutivacaftor. Manufacturer advises adjus... |
| Dexamethasone | SEVERE | Clarithromycin is predicted to increase the exposure to Dexamethasone. Manufacturer advises avoid... |
| Digoxin | SEVERE | Clarithromycin increases the concentration of Digoxin. Manufacturer advises monitor Digoxin conce... |
| Diltiazem | SEVERE | Clarithromycin is predicted to increase the exposure to Diltiazem. Manufacturer advises caution. |
| Docetaxel | SEVERE | Clarithromycin is predicted to increase the exposure to Docetaxel. Manufacturer advises avoid or ... |
| Domperidone | SEVERE | Clarithromycin is predicted to increase the exposure to Domperidone. Manufacturer advises avoid. |
| Dronedarone | SEVERE | Clarithromycin very markedly increases the exposure to Dronedarone. Manufacturer advises avoid. |
| Drospirenone | SEVERE | Clarithromycin is predicted to increase the exposure to Drospirenone. Manufacturer makes no recom... |
| Elacestrant | SEVERE | Clarithromycin is predicted to increase the exposure to Elacestrant. Manufacturer advises avoid p... |
| Eletriptan | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Eletriptan. Manufacturer advises... |
| Elexacaftor | SEVERE | Clarithromycin is predicted to increase the exposure to Elexacaftor. Manufacturer advises adjust ... |
| Eliglustat | SEVERE | Clarithromycin is predicted to increase the exposure to Eliglustat. Manufacturer advises avoid or... |
| Encorafenib | SEVERE | Clarithromycin is predicted to increase the exposure to Encorafenib. Manufacturer advises avoid o... |
| Enfortumab vedotin | SEVERE | Clarithromycin is predicted to increase the exposure to the cytotoxic component of Enfortumab ved... |
| Entrectinib | SEVERE | Clarithromycin is predicted to increase the exposure to Entrectinib. Manufacturer advises avoid o... |
| Eplerenone | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Eplerenone. Manufacturer advises... |
| Erdafitinib | SEVERE | Clarithromycin is predicted to increase the exposure to Erdafitinib. Manufacturer advises adjust ... |
| Ergometrine | SEVERE | Clarithromycin is predicted to increase the risk of ergotism when given with Ergometrine. Manufac... |
| Erlotinib | SEVERE | Clarithromycin is predicted to increase the exposure to Erlotinib. Manufacturer advises use with ... |
| Etrasimod | SEVERE | Clarithromycin is predicted to increase the exposure to Etrasimod. Manufacturer advises avoid in ... |
| Etravirine | SEVERE | Etravirine decreases the exposure to Clarithromycin and Clarithromycin slightly increases the exp... |
| Everolimus | SEVERE | Clarithromycin is predicted to increase the exposure to Everolimus. Manufacturer advises avoid. |
| Fentanyl | SEVERE | Clarithromycin is predicted to increase the exposure to Fentanyl. Manufacturer advises monitor an... |
| Fesoterodine | SEVERE | Clarithromycin is predicted to moderately increase the exposure to Fesoterodine. Manufacturer adv... |
| Finerenone | SEVERE | Clarithromycin is predicted to increase the exposure to Finerenone. Manufacturer advises avoid. |
| Fludrocortisone | SEVERE | Clarithromycin is predicted to increase the exposure to Fludrocortisone. Manufacturer advises avo... |
| Fluticasone | SEVERE | Clarithromycin is predicted to increase the exposure to Fluticasone. Manufacturer advises avoid o... |
| Fosamprenavir | SEVERE | Fosamprenavir boosted with ritonavir is predicted to increase the exposure to Clarithromycin. Man... |
| Gefitinib | SEVERE | Clarithromycin is predicted to increase the exposure to Gefitinib. Manufacturer advises monitor a... |
| Glasdegib | SEVERE | Clarithromycin is predicted to increase the exposure to Glasdegib. Manufacturer advises use with ... |
| Grazoprevir | SEVERE | Clarithromycin is predicted to moderately to markedly increase the exposure to Grazoprevir. Manuf... |
| Hydrocortisone | SEVERE | Clarithromycin is predicted to increase the exposure to Hydrocortisone. Manufacturer advises avoi... |
| Hydroxychloroquine | SEVERE | Clarithromycin might increase the risk of serious cardiovascular adverse effects when given with ... |
| Ibrutinib | SEVERE | Clarithromycin is predicted to increase the exposure to Ibrutinib. Manufacturer advises avoid or ... |
| Insulin | SEVERE | Clarithromycin has been reported to cause hypoglycaemia when given with Insulin. Manufacturer adv... |
| Irinotecan | SEVERE | Clarithromycin is predicted to increase the exposure to the active metabolite of Irinotecan. Manu... |
| Isavuconazole | SEVERE | Clarithromycin is predicted to increase the exposure to Isavuconazole. Manufacturer advises avoid... |
| Ivabradine | SEVERE | Clarithromycin is predicted to increase the exposure to Ivabradine. Manufacturer advises avoid. |
| Ivacaftor | SEVERE | Clarithromycin is predicted to increase the exposure to Ivacaftor. Manufacturer advises adjust do... |
| Ivosidenib | SEVERE | Clarithromycin is predicted to increase the exposure to Ivosidenib. Manufacturer advises monitor ... |
| Lercanidipine | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Lercanidipine. Manufacturer advi... |
| Lomitapide | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Lomitapide. Manufacturer advises... |
| Lopinavir | SEVERE | Lopinavir boosted with ritonavir is predicted to increase the exposure to Clarithromycin. Manufac... |
| Lorlatinib | SEVERE | Clarithromycin is predicted to increase the exposure to Lorlatinib. Manufacturer advises avoid or... |
| Lurasidone | SEVERE | Clarithromycin is predicted to increase the exposure to Lurasidone. Manufacturer advises avoid. |
| Maraviroc | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Maraviroc. Manufacturer advises ... |
| Mavacamten | SEVERE | Clarithromycin is predicted to increase the exposure to Mavacamten. Manufacturer advises avoid or... |
| Methadone | SEVERE | Clarithromycin is predicted to increase the concentration of Methadone. Manufacturer makes no rec... |
| Methylprednisolone | SEVERE | Clarithromycin is predicted to increase the exposure to Methylprednisolone. Manufacturer advises ... |
| Midazolam | SEVERE | Clarithromycin is predicted to markedly to very markedly increase the exposure to Midazolam. Manu... |
| Midostaurin | SEVERE | Clarithromycin is predicted to increase the exposure to Midostaurin. Manufacturer advises avoid o... |
| Mizolastine | SEVERE | Clarithromycin is predicted to increase the exposure to Mizolastine. Manufacturer advises avoid. |
| Mometasone | SEVERE | Clarithromycin is predicted to increase the exposure to Mometasone. Manufacturer advises avoid or... |
| Naloxegol | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Naloxegol. Manufacturer advises ... |
| Neratinib | SEVERE | Clarithromycin is predicted to increase the exposure to Neratinib. Manufacturer advises avoid or ... |
| Nilotinib | SEVERE | Clarithromycin is predicted to increase the exposure to Nilotinib. Manufacturer advises avoid. |
| Omaveloxolone | SEVERE | Clarithromycin is predicted to increase the exposure to Omaveloxolone. Manufacturer advises avoid... |
| Oxycodone | SEVERE | Clarithromycin is predicted to increase the exposure to Oxycodone. Manufacturer advises monitor a... |
| Palbociclib | SEVERE | Clarithromycin is predicted to increase the exposure to Palbociclib. Manufacturer advises avoid o... |
| Pemigatinib | SEVERE | Clarithromycin is predicted to increase the exposure to Pemigatinib. Manufacturer advises avoid o... |
| Pimozide | SEVERE | Clarithromycin is predicted to increase the exposure to Pimozide. Manufacturer advises avoid. |
| Piperaquine | SEVERE | Clarithromycin is predicted to increase the concentration of Piperaquine. Manufacturer advises ca... |
| Pravastatin | SEVERE | Clarithromycin moderately increases the exposure to Pravastatin. Manufacturer advises caution. |
| Prednisolone | SEVERE | Clarithromycin is predicted to increase the exposure to Prednisolone. Manufacturer advises avoid ... |
| Propafenone | SEVERE | Clarithromycin is predicted to increase the exposure to Propafenone. Manufacturer advises monitor... |
| Quetiapine | SEVERE | Clarithromycin is predicted to increase the exposure to Quetiapine. Manufacturer advises avoid. |
| Quizartinib | SEVERE | Clarithromycin is predicted to increase the exposure to Quizartinib. Manufacturer advises adjust ... |
| Ranolazine | SEVERE | Clarithromycin is predicted to increase the exposure to Ranolazine. Manufacturer advises avoid. |
| Rifabutin | SEVERE | Rifabutin decreases the concentration of Clarithromycin and Clarithromycin increases the concentr... |
| Rifampicin | SEVERE | Rifampicin greatly decreases the concentration of Clarithromycin. Manufacturer makes no recommend... |
| Ritonavir | SEVERE | Ritonavir increases the exposure to Clarithromycin. Manufacturer advises adjust dose in renal imp... |
| Salmeterol | SEVERE | Clarithromycin is predicted to increase the exposure to Salmeterol. Manufacturer advises avoid. |
| Selumetinib | SEVERE | Clarithromycin is predicted to increase the exposure to Selumetinib. Manufacturer advises avoid o... |
| Sildenafil | SEVERE | Clarithromycin is predicted to increase the exposure to Sildenafil. Manufacturer advises avoid po... |
| Simvastatin | SEVERE | Clarithromycin is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Siponimod | SEVERE | Clarithromycin is predicted to increase the exposure to Siponimod. Manufacturer advises avoid dep... |
| Sirolimus | SEVERE | Clarithromycin is predicted to increase the concentration of Sirolimus. Manufacturer advises avoi... |
| Solifenacin | SEVERE | Clarithromycin is predicted to increase the exposure to Solifenacin. Manufacturer advises adjust ... |
| Sparsentan | SEVERE | Clarithromycin is predicted to increase the exposure to Sparsentan. Manufacturer advises avoid. |
| Tacrolimus | SEVERE | Clarithromycin is predicted to increase the concentration of Tacrolimus. Manufacturer advises avo... |
| Tadalafil | SEVERE | Clarithromycin is predicted to increase the exposure to Tadalafil. Manufacturer advises use with ... |
| Talazoparib | SEVERE | Clarithromycin is predicted to slightly increase the exposure to Talazoparib. Manufacturer advise... |
| Temsirolimus | SEVERE | Clarithromycin is predicted to increase the concentration of Temsirolimus. Manufacturer advises a... |
| Tezacaftor | SEVERE | Clarithromycin is predicted to increase the exposure to Tezacaftor. Manufacturer advises adjust d... |
| Ticagrelor | SEVERE | Clarithromycin is predicted to markedly increase the exposure to Ticagrelor. Manufacturer advises... |
| Tolterodine | SEVERE | Clarithromycin is predicted to increase the exposure to Tolterodine. Manufacturer advises avoid. |
| Tolvaptan | SEVERE | Clarithromycin is predicted to increase the exposure to Tolvaptan. Manufacturer advises caution o... |
| Topotecan | SEVERE | Clarithromycin is predicted to increase the exposure to Topotecan. Manufacturer advises monitor. |
| Trabectedin | SEVERE | Clarithromycin is predicted to increase the exposure to Trabectedin. Manufacturer advises avoid o... |
| Trastuzumab emtansine | SEVERE | Clarithromycin is predicted to increase the exposure to the cytotoxic component of Trastuzumab em... |
| Triamcinolone | SEVERE | Clarithromycin is predicted to increase the exposure to Triamcinolone. Manufacturer advises avoid... |
| Ulipristal | SEVERE | Clarithromycin is predicted to increase the exposure to Ulipristal. Manufacturer advises avoid wh... |
| Upadacitinib | SEVERE | Clarithromycin is predicted to increase the exposure to Upadacitinib. Manufacturer advises cautio... |
| Vamorolone | SEVERE | Clarithromycin is predicted to increase the exposure to Vamorolone. Manufacturer advises adjust d... |
| Vanzacaftor | SEVERE | Clarithromycin is predicted to increase the exposure to Vanzacaftor. Manufacturer advises adjust ... |
| Vardenafil | SEVERE | Clarithromycin is predicted to increase the exposure to Vardenafil. Manufacturer advises avoid. |
| Vemurafenib | SEVERE | Clarithromycin is predicted to increase the exposure to Vemurafenib. Manufacturer advises caution. |
| Venetoclax | SEVERE | Clarithromycin is predicted to increase the exposure to Venetoclax. Manufacturer advises avoid or... |
| Verapamil | SEVERE | Clarithromycin is predicted to increase the exposure to Verapamil. Manufacturer advises monitor. |
| Vinblastine | SEVERE | Clarithromycin is predicted to increase the exposure to Vinblastine. Manufacturer advises caution. |
| Vincristine | SEVERE | Clarithromycin is predicted to increase the exposure to Vincristine. Manufacturer advises caution. |
| Vindesine | SEVERE | Clarithromycin is predicted to increase the exposure to Vindesine. Manufacturer advises caution. |
| Vinorelbine | SEVERE | Clarithromycin is predicted to increase the exposure to Vinorelbine. Manufacturer advises caution. |
| Voclosporin | SEVERE | Clarithromycin is predicted to increase the exposure to Voclosporin. Manufacturer advises avoid. |
| Warfarin | SEVERE | Clarithromycin increases the anticoagulant effect of Warfarin. Manufacturer advises monitor INR a... |
| Afatinib | MODERATE | Clarithromycin is predicted to increase the exposure to Afatinib. Manufacturer advises separating... |
| Alfuzosin | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Alfuzosin. Manufacturer advise... |
| Aliskiren | MODERATE | Clarithromycin is predicted to increase the exposure to Aliskiren. Manufacturer advises caution. |
| Alitretinoin | MODERATE | Clarithromycin is predicted to increase the exposure to Alitretinoin. Manufacturer advises adjust... |
| Alprazolam | MODERATE | Clarithromycin moderately increases the exposure to Alprazolam. Manufacturer advises avoid. |
| Aminophylline | MODERATE | Clarithromycin is predicted to increase the exposure to Aminophylline. Manufacturer advises adjus... |
| Amiodarone | MODERATE | Clarithromycin is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Amlodipine | MODERATE | Clarithromycin is predicted to increase the exposure to Amlodipine. Manufacturer advises monitor ... |
| Apixaban | MODERATE | Clarithromycin slightly increases the exposure to Apixaban. Manufacturer makes no recommendation. |
| Aprepitant | MODERATE | Clarithromycin is predicted to markedly increase the exposure to Aprepitant. Manufacturer advises... |
| Aripiprazole | MODERATE | Clarithromycin is predicted to slightly increase the exposure to Aripiprazole. Manufacturer advis... |
| Atogepant | MODERATE | Clarithromycin is predicted to increase the exposure to Atogepant. Manufacturer advises adjust At... |
| Avapritinib | MODERATE | Clarithromycin is predicted to increase the exposure to Avapritinib. Manufacturer advises avoid. |
| Axitinib | MODERATE | Clarithromycin is predicted to increase the exposure to Axitinib. Manufacturer advises avoid or a... |
| Beclometasone | MODERATE | Clarithromycin is predicted to increase the exposure to Beclometasone (risk with beclometasone is... |
| Bictegravir | MODERATE | Clarithromycin is predicted to increase the exposure to Bictegravir. Manufacturer advises use wit... |
| Bortezomib | MODERATE | Clarithromycin slightly increases the exposure to Bortezomib. Manufacturer advises monitor. |
| Bosentan | MODERATE | Clarithromycin is predicted to increase the exposure to Bosentan. Manufacturer makes no recommend... |
| Cabozantinib | MODERATE | Clarithromycin is predicted to increase the exposure to Cabozantinib. Manufacturer advises caution. |
| Capivasertib | MODERATE | Clarithromycin is predicted to increase the exposure to Capivasertib. Manufacturer advises adjust... |
| Cilostazol | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Cilostazol. Manufacturer advis... |
| Cinacalcet | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Cinacalcet. Manufacturer advis... |
| Crizotinib | MODERATE | Clarithromycin is predicted to increase the exposure to Crizotinib. Manufacturer advises avoid. |
| Dabigatran | MODERATE | Clarithromycin increases the exposure to Dabigatran. Manufacturer advises monitor. |
| Dabrafenib | MODERATE | Clarithromycin is predicted to increase the exposure to Dabrafenib. Manufacturer advises use with... |
| Darolutamide | MODERATE | Clarithromycin is predicted to increase the exposure to Darolutamide. Manufacturer advises monito... |
| Dienogest | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Dienogest. Manufacturer makes ... |
| Doxazosin | MODERATE | Clarithromycin is predicted to increase the exposure to Doxazosin. Manufacturer makes no recommen... |
| Dutasteride | MODERATE | Clarithromycin is predicted to increase the exposure to Dutasteride. Manufacturer advises monitor... |
| Edoxaban | MODERATE | Clarithromycin slightly increases the exposure to Edoxaban. Manufacturer advises caution. |
| Efavirenz | MODERATE | Efavirenz decreases the exposure to Clarithromycin. Manufacturer advises consider alternatives. |
| Enzalutamide | MODERATE | Enzalutamide is predicted to affect the exposure to Clarithromycin. Manufacturer advises use with... |
| Esketamine | MODERATE | Clarithromycin is predicted to increase the exposure to Esketamine. Manufacturer advises adjust d... |
| Eszopiclone | MODERATE | Clarithromycin is predicted to increase the exposure to Eszopiclone. Manufacturer advises adjust ... |
| Etonogestrel | MODERATE | Clarithromycin is predicted to increase the concentration of subdermal Etonogestrel. Manufacturer... |
| Fedratinib | MODERATE | Clarithromycin is predicted to increase the exposure to Fedratinib. Manufacturer advises adjust d... |
| Felodipine | MODERATE | Clarithromycin is predicted to increase the exposure to Felodipine. Manufacturer advises monitor ... |
| Fexofenadine | MODERATE | Clarithromycin is predicted to increase the exposure to Fexofenadine. Manufacturer makes no recom... |
| Fidaxomicin | MODERATE | Clarithromycin is predicted to increase the exposure to Fidaxomicin. Manufacturer advises avoid. |
| Fosaprepitant | MODERATE | Clarithromycin is predicted to increase the exposure to Fosaprepitant. Manufacturer advises caution. |
| Fostamatinib | MODERATE | Clarithromycin is predicted to increase the exposure to Fostamatinib. Manufacturer advises monito... |
| Futibatinib | MODERATE | Clarithromycin is predicted to increase the exposure to Futibatinib. Manufacturer advises avoid o... |
| Galantamine | MODERATE | Clarithromycin is predicted to increase the exposure to Galantamine. Manufacturer advises monitor... |
| Gilteritinib | MODERATE | Clarithromycin is predicted to increase the exposure to Gilteritinib. Manufacturer advises cautio... |
| Glibenclamide | MODERATE | Clarithromycin might increase the exposure to Glibenclamide. Manufacturer advises monitor blood g... |
| Gliclazide | MODERATE | Clarithromycin might increase the exposure to Gliclazide. Manufacturer advises monitor blood gluc... |
| Glimepiride | MODERATE | Clarithromycin might increase the exposure to Glimepiride. Manufacturer advises monitor blood glu... |
| Glipizide | MODERATE | Clarithromycin might increase the exposure to Glipizide. Manufacturer advises monitor blood glucose. |
| Guanfacine | MODERATE | Clarithromycin is predicted to increase the exposure to Guanfacine. Manufacturer advises adjust G... |
| Idelalisib | MODERATE | Clarithromycin is predicted to increase the exposure to Idelalisib. Manufacturer advises monitor. |
| Imatinib | MODERATE | Clarithromycin is predicted to increase the exposure to Imatinib. Manufacturer advises caution. |
| Ketamine | MODERATE | Clarithromycin is predicted to increase the exposure to Ketamine. Manufacturer advises adjust dose. |
| Lacidipine | MODERATE | Clarithromycin is predicted to increase the exposure to Lacidipine. Manufacturer advises monitor ... |
| Lapatinib | MODERATE | Clarithromycin is predicted to increase the exposure to Lapatinib. Manufacturer advises avoid. |
| Larotrectinib | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Larotrectinib. Manufacturer ad... |
| Leniolisib | MODERATE | Clarithromycin is predicted to increase the exposure to Leniolisib. Manufacturer advises avoid. |
| Letermovir | MODERATE | Clarithromycin is predicted to increase the concentration of Letermovir. Manufacturer advises cau... |
| Lidocaine | MODERATE | Clarithromycin is predicted to increase the exposure to Lidocaine. Manufacturer makes no recommen... |
| Linezolid | MODERATE | Clarithromycin increases the exposure to Linezolid. Manufacturer makes no recommendation. |
| Lumacaftor | MODERATE | Lumacaftor is predicted to decrease the exposure to Clarithromycin. Manufacturer advises consider... |
| Macitentan | MODERATE | Clarithromycin is predicted to increase the exposure to Macitentan. Manufacturer advises caution. |
| Medroxyprogesterone | MODERATE | Clarithromycin is predicted to increase the concentration of intramuscular Medroxyprogesterone. M... |
| Mirabegron | MODERATE | Clarithromycin is predicted to increase the exposure to Mirabegron. Manufacturer advises adjust M... |
| Mirtazapine | MODERATE | Clarithromycin is predicted to increase the exposure to Mirtazapine. Manufacturer advises caution. |
| Momelotinib | MODERATE | Clarithromycin is predicted to increase the exposure to Momelotinib. Manufacturer advises caution... |
| Nadolol | MODERATE | Clarithromycin is predicted to increase the exposure to Nadolol. Manufacturer makes no recommenda... |
| Naldemedine | MODERATE | Clarithromycin is predicted to increase the exposure to Naldemedine. Manufacturer advises avoid o... |
| Netupitant | MODERATE | Clarithromycin is predicted to increase the exposure to Netupitant. Manufacturer advises caution. |
| Nevirapine | MODERATE | Nevirapine decreases the exposure to Clarithromycin. Manufacturer advises consider alternatives. |
| Nicardipine | MODERATE | Clarithromycin is predicted to increase the exposure to Nicardipine. Manufacturer advises monitor... |
| Nifedipine | MODERATE | Clarithromycin is predicted to increase the exposure to Nifedipine. Manufacturer advises monitor ... |
| Nimodipine | MODERATE | Clarithromycin is predicted to increase the exposure to Nimodipine. Manufacturer advises monitor ... |
| Nintedanib | MODERATE | Clarithromycin is predicted to increase the exposure to Nintedanib. Manufacturer advises monitor. |
| Nirmatrelvir | MODERATE | Nirmatrelvir boosted with ritonavir is predicted to increase the concentration of Clarithromycin.... |
| Nitisinone | MODERATE | Clarithromycin is predicted to increase the exposure to Nitisinone. Manufacturer advises adjust d... |
| Olaparib | MODERATE | Clarithromycin is predicted to increase the exposure to Olaparib. Manufacturer advises avoid or a... |
| Osilodrostat | MODERATE | Clarithromycin is predicted to increase the exposure to Osilodrostat. Manufacturer advises cautio... |
| Ospemifene | MODERATE | Clarithromycin is predicted to increase the exposure to Ospemifene. Manufacturer advises avoid in... |
| Paclitaxel | MODERATE | Clarithromycin is predicted to increase the exposure to Paclitaxel. Manufacturer advises caution. |
| Panobinostat | MODERATE | Clarithromycin is predicted to increase the exposure to Panobinostat. Manufacturer advises adjust... |
| Paricalcitol | MODERATE | Clarithromycin is predicted to increase the exposure to Paricalcitol. Manufacturer advises caution. |
| Pazopanib | MODERATE | Clarithromycin is predicted to increase the exposure to Pazopanib. Manufacturer advises avoid or ... |
| Pibrentasvir | MODERATE | Clarithromycin is predicted to increase the exposure to Pibrentasvir. Manufacturer makes no recom... |
| Pioglitazone | MODERATE | Clarithromycin might cause hypoglycaemia when given with Pioglitazone. Manufacturer advises monit... |
| Polatuzumab vedotin | MODERATE | Clarithromycin is predicted to increase the exposure to Polatuzumab vedotin. Manufacturer advises... |
| Ponatinib | MODERATE | Clarithromycin is predicted to slightly increase the exposure to Ponatinib. Manufacturer advises ... |
| Pralsetinib | MODERATE | Clarithromycin is predicted to increase the exposure to Pralsetinib. Manufacturer advises avoid o... |
| Propiverine | MODERATE | Clarithromycin given with carbimazole is predicted to increase the exposure to Propiverine. Manuf... |
| Reboxetine | MODERATE | Clarithromycin is predicted to increase the exposure to Reboxetine. Manufacturer advises avoid. |
| Regorafenib | MODERATE | Clarithromycin is predicted to increase the exposure to Regorafenib. Manufacturer advises avoid. |
| Relugolix | MODERATE | Clarithromycin is predicted to increase the exposure to Relugolix. Manufacturer advises avoid or ... |
| Repaglinide | MODERATE | Clarithromycin might cause hypoglycaemia when given with Repaglinide. Manufacturer advises monito... |
| Ribociclib | MODERATE | Clarithromycin is predicted to increase the exposure to Ribociclib. Manufacturer advises avoid or... |
| Rimegepant | MODERATE | Clarithromycin is predicted to increase the exposure to Rimegepant. Manufacturer advises avoid. |
| Ripretinib | MODERATE | Clarithromycin is predicted to increase the exposure to Ripretinib. Manufacturer advises monitor. |
| Risperidone | MODERATE | Clarithromycin is predicted to increase the exposure to Risperidone. Manufacturer advises adjust ... |
| Rivaroxaban | MODERATE | Clarithromycin slightly increases the exposure to Rivaroxaban. Manufacturer advises caution in re... |
| Rupatadine | MODERATE | Clarithromycin is predicted to increase the exposure to Rupatadine. Manufacturer advises avoid. |
| Ruxolitinib | MODERATE | Clarithromycin is predicted to increase the exposure to Ruxolitinib. Manufacturer advises adjust ... |
| Saxagliptin | MODERATE | Clarithromycin is predicted to increase the exposure to Saxagliptin. Manufacturer makes no recomm... |
| Selpercatinib | MODERATE | Clarithromycin is predicted to increase the exposure to Selpercatinib. Manufacturer advises adjus... |
| Sertraline | MODERATE | Clarithromycin is predicted to increase the exposure to Sertraline. Manufacturer advises avoid. |
| Sufentanil | MODERATE | Clarithromycin is predicted to increase the exposure to Sufentanil. Manufacturer advises separati... |
| Sunitinib | MODERATE | Clarithromycin is predicted to increase the exposure to Sunitinib. Manufacturer advises avoid or ... |
| Tamsulosin | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Tamsulosin. Manufacturer advis... |
| Theophylline | MODERATE | Clarithromycin is predicted to increase the exposure to Theophylline. Manufacturer advises adjust... |
| Tofacitinib | MODERATE | Clarithromycin is predicted to increase the exposure to Tofacitinib. Manufacturer advises adjust ... |
| Tolbutamide | MODERATE | Clarithromycin might increase the exposure to Tolbutamide. Manufacturer advises monitor blood glu... |
| Toremifene | MODERATE | Clarithromycin is predicted to increase the exposure to Toremifene. Manufacturer advises caution. |
| Trametinib | MODERATE | Clarithromycin is predicted to increase the concentration of Trametinib. Manufacturer advises cau... |
| Trazodone | MODERATE | Clarithromycin is predicted to moderately increase the exposure to Trazodone. Manufacturer advise... |
| Venlafaxine | MODERATE | Clarithromycin is predicted to increase the exposure to Venlafaxine. Manufacturer advises caution. |
| Zanubrutinib | MODERATE | Clarithromycin is predicted to increase the exposure to Zanubrutinib. Manufacturer advises avoid ... |
| Zidovudine | MODERATE | Clarithromycin decreases the absorption of Zidovudine. Manufacturer advises separate administrati... |
| Zopiclone | MODERATE | Clarithromycin is predicted to increase the exposure to Zopiclone. Manufacturer advises adjust dose. |
| Almotriptan | MILD | Clarithromycin increases the exposure to Almotriptan. Manufacturer makes no recommendation. |
| Apalutamide | MILD | Clarithromycin is predicted to increase the exposure to Apalutamide. Manufacturer advises monitor... |
| Bedaquiline | MILD | Clarithromycin might increase the exposure to Bedaquiline. Manufacturer makes no recommendation. |
| Cannabidiol | MILD | Clarithromycin is predicted to increase the exposure to Cannabidiol. Manufacturer advises avoid o... |
| Dronabinol | MILD | Clarithromycin is predicted to increase the exposure to Dronabinol. Manufacturer advises adjust d... |
| Modafinil | MILD | Clarithromycin is predicted to increase the exposure to Modafinil. Manufacturer makes no recommen... |
| Oxybutynin | MILD | Clarithromycin is predicted to increase the exposure to Oxybutynin. Manufacturer makes no recomme... |
| Perampanel | MILD | Clarithromycin is predicted to very slightly increase the exposure to Perampanel. Manufacturer ma... |
| Praziquantel | MILD | Clarithromycin is predicted to moderately increase the exposure to Praziquantel. Manufacturer adv... |
| Tigecycline | MILD | Clarithromycin might increase the exposure to Tigecycline. Manufacturer makes no recommendation. |
Check Clarithromycin against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker